{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["VanCleave A"],"funding":["NCI NIH HHS","NIGMS NIH HHS"],"pagination":["2597-2610"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7343631"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(27)"],"pubmed_abstract":["Outcomes have not improved for metastatic osteosarcoma for several decades. In part, this failure to develop better therapies stems from a lack of understanding of osteosarcoma biology, given the rarity of the disease and the high genetic heterogeneity at the time of diagnosis. We report here the successful establishment of a new human osteosarcoma cell line, COS-33, from a patient-derived xenograft and demonstrate retention of the biological features of the original tumor. We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway. Suppressed mTOR signaling after treatment with rapamycin was confirmed by decreased phosphorylation of the S6 ribosomal protein. Increasing concentrations of rapam"],"journal":["Oncotarget"],"pubmed_title":["Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway."],"pmcid":["PMC7343631"],"funding_grant_id":["P30 CA042014","P20 GM103548","P20 GM103620"],"pubmed_authors":["Ross A","Rao P","Tao J","Torres H","Fang F","Zheng S","Li Q","Evans C","Fuglsby K","Rodezno T","Leiferman P","Palmer M","Afeworki Y","Houghton P","VanCleave A"],"additional_accession":[]},"is_claimable":false,"name":"Development and characterization of the novel human osteosarcoma cell line COS-33 with sustained activation of the mTOR pathway.","description":"Outcomes have not improved for metastatic osteosarcoma for several decades. In part, this failure to develop better therapies stems from a lack of understanding of osteosarcoma biology, given the rarity of the disease and the high genetic heterogeneity at the time of diagnosis. We report here the successful establishment of a new human osteosarcoma cell line, COS-33, from a patient-derived xenograft and demonstrate retention of the biological features of the original tumor. We found high mTOR signaling activity in the cultured cells, which were sensitive to a small molecule inhibitor, rapamycin, a suppressor of the mTOR pathway. Suppressed mTOR signaling after treatment with rapamycin was confirmed by decreased phosphorylation of the S6 ribosomal protein. Increasing concentrations of rapam","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-04-29T08:44:37.014Z","creation":"2021-02-19T22:03:42Z"},"accession":"S-EPMC7343631","cross_references":{"pubmed":["32676162"],"doi":["10.18632/oncotarget.27611"]}}